Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

Prymula, Roman; Hanovcová, I; Splino, M; Kriz, Pavla; Motlová, J; Lebedova, Vera; Lommel, Patricia; Kaliskova, Eva; Pascal, Thierry; Borys, Dorota

doi:10.1016/j.vaccine.2010.12.086

Cited by 68 publications

(50 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally the assumption that PCV10 has effectiveness against NTHi disease has been widely and repeatedly challenged. [22][23][24][26][27][28][29][30][31][32] In addition, of note, by definition, IPD is a severe condition caused by streptococcus pnemoniae, not caused by NTHi. The assumption that PCV10 provided protection against invasive NTHi is not supported by any scientific evidence.…”

Section: Discussionmentioning

confidence: 99%

“…Some models of pneumococcal vaccination have assumed additional impact of PCV10 on otitis media due to inclusion of a carrier protein derived from non-typable Haemophilus influenza (NTHi), with reference by trial results from an investigational pre-cursor to the current formulation. 27 However, 2 recent clinical trials comparing PCV10 to placebo report all-cause otitis media report reductions in a range expected of a vaccine specific to pneumococcal disease; 30,31 one of the 2 specified bacterial outcomes and reported no effectiveness vs. AOM caused by NTHi. 27 Further, a recently published randomized study comparing PCV7 and PCV10 on nasopharyngeal carriage found no impact of PCV10 on NTHi carriage compared to PCV7.…”

Section: Discussionmentioning

confidence: 99%

“…27 However, 2 recent clinical trials comparing PCV10 to placebo report all-cause otitis media report reductions in a range expected of a vaccine specific to pneumococcal disease; 30,31 one of the 2 specified bacterial outcomes and reported no effectiveness vs. AOM caused by NTHi. 27 Further, a recently published randomized study comparing PCV7 and PCV10 on nasopharyngeal carriage found no impact of PCV10 on NTHi carriage compared to PCV7. 26 Therefore, there is no evidence to support an impact of PCV10 on otitis media greater than that expected from the pneumococcal serotypes contained in the vaccine.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Keywords: herd effect, incremental cost-effectiveness ratio (ICER), Markov transition-state model, pneumococcal disease, 13-valent pneumococcal conjugate vaccine (PCV13), 10-valent pneumococcal conjugate vaccine (PCV10)Pneumococcal disease causes large morbidity, mortality and health care utilization and medical and non-medical costs, which can all be reduced by effective infant universal routine immunization programs with pneumococcal conjugate vaccines (PCV). We evaluated the clinical and economic benefits of such programs with either 10-or 13-valent PCVs in Malaysia and Hong Kong by using an age-stratified Markov cohort model with many country-specific inputs. The incremental cost per quality-adjusted life year (QALY) was calculated to compare PCV10 or PCV13 against no vaccination and PCV13 against PCV10 over a 10-year birth cohort's vaccination. Both payer and societal perspectives were used. PCV13 had better public health and economic outcomes than a PCV10 program across all scenarios considered. For example, in the base case scenario in Malaysia, PCV13 would reduce more cases of IPD (C2,296), pneumonia (C705,281), and acute otitis media (C376,967) and save more lives (C6,122) than PCV10. Similarly, in Hong Kong, PCV13 would reduce more cases of IPD cases (C529), pneumonia (C172,185), and acute otitis media (C37,727) and save more lives (C2,688) than PCV10. During the same time horizon, PCV13 would gain over 74,000 and 21,600 additional QALYs than PCV10 in Malaysia and Hong Kong, respectively. PCV13 would be cost saving when compared against similar program with PCV10, under both payer and societal perspective in both countries. PCV13 remained a better choice over PCV10 in multiple sensitivity, scenario, and probabilistic analyses. PCV13s broader serotype coverage in its formulation and herd effect compared against PCV10 were important drivers of differences in outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Roberts

Lee

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Trials to evaluate the immunogenicity of PHiD-CV coadministered with DTPw-HBV/Hib (diphtheria-tetanus-whole-cell pertussis-hepatitis B vaccine/Haemophilus influenzae type b vaccine) or DTPw-HBV/Hib plus IPV in young infants at 2, 4, and 6 months or 6, 10, and 14 weeks of age demonstrated that the vaccine was immunogenic against each of the 10 pneumococcal vaccine serotypes. The vaccine had no significant effect on reducing nasopharyngeal carriage of nontypeable H. influenzae but did reduce carriage of vaccine-type pneumococci after the primary series and a booster dose of vaccine at 12 to 15 months were given (6,93). Further studies to assess booster vaccination outcomes and vaccine efficacy are currently ongoing.…”

Section: Currently Licensed Vaccinesmentioning

confidence: 99%

Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

2012

View full text Add to dashboard Cite

SUMMARY Invasive infections caused by Streptococcus pneumoniae continue to be a major cause of morbidity and mortality worldwide, especially in children under 5 years of age. In the United States, 90% of invasive pneumococcal infections in children are caused by 13 serotypes of S. pneumoniae . The licensure (in 2000) and subsequent widespread use of a heptavalent pneumococcal conjugate vaccine (PCV7) have had a significant impact on decreasing the incidence of serious invasive pneumococcal disease (IPD) in all age groups, especially in children under 2 years of age. However, the emergence of replacement non-PCV7 serotypes, especially serotype 19A, has resulted in an increase in the incidence of serious and invasive infections. In 2010, a 13-valent PCV was licensed in the United States. However, the impact that this vaccine will have on IPD remains to be seen. The objectives of this review are to discuss the epidemiology of serious and invasive pneumococcal infections in the United States in the PCV era and to review some of the pneumococcal vaccines that are in development.

show abstract

“…An 11-valent precursor to PHiD-CV reduced NTHi-associated acute otitis media by 35% (12). Although a reduction in H. influenzae nasopharyngeal carriage was observed following primary and booster vaccination with the 11-valent vaccine (17), no substantial effect has been observed on NTHi carriage in subsequent studies with PHiD-CV, which has 8 of 10 serotypes conjugated to protein D (20,21). Whether or not PHiD-CV will afford protection against OM or other NTHi infections, particularly in high-risk populations, is yet to be determined.…”

mentioning

confidence: 99%

A PCR–High-Resolution Melt Assay for Rapid Differentiation of Nontypeable Haemophilus influenzae and Haemophilus haemolyticus

et al. 2014

View full text Add to dashboard Cite

show abstract

Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

Cited by 68 publications

References 39 publications

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

A PCR–High-Resolution Melt Assay for Rapid Differentiation of Nontypeable Haemophilus influenzae and Haemophilus haemolyticus

Contact Info

Product

Resources

About